AMINOLOGICS CO.,LTD. Logo

AMINOLOGICS CO.,LTD.

Manufactures high-purity chiral amino acids & APIs for pharma, chemical, and food industries.

074430 | KO

Overview

Corporate Details

ISIN(s):
KR7074430000
LEI:
Country:
South Korea
Address:
서울특별시 강남구 역삼로 151 삼오빌딩3층 301호, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AMINOLOGICS CO., LTD. is a specialty manufacturer of amino acids and their derivatives. The company focuses on producing high-purity chiral amino acids using its proprietary and patented platform technology, ARCA (Alanine Racemase Chiral). This innovative technology allows for the cost-effective separation and production of amino acids with high optical purity. AMINOLOGICS supplies these amino-acid-based raw materials, including Active Pharmaceutical Ingredients (APIs), to various industrial fields such as pharmaceuticals, fine chemicals, agrochemicals, and the food and feed industries, catering to both research and large-scale production needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 66.7 KB
2025-06-30 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-06-26 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 86.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 930.5 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.1 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 24.8 KB
2025-03-21 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.3 MB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 157.5 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 138.0 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.7 KB
2025-02-27 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.6 KB
2025-01-31 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB
2024-12-12 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-08 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 944.5 KB

Automate Your Workflow. Get a real-time feed of all AMINOLOGICS CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AMINOLOGICS CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AMINOLOGICS CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.